Breast Cancer Real-World Insights and Decision Guidance Evaluation in Hong Kong - BRIDGE-HK

Inclusion Criteria

• Inclusion Criteria:
• - 1.Female sex
• - 2.Age ≥18 years at the time of breast cancer diagnosis (index date)
• - 3.Histologically confirmed diagnosis of breast cancer (invasive or in situ) recorded in the HA database in all available records
• - 4.Documentation of surgery, or at least one systemic therapy (chemotherapy, endocrine therapy, targeted therapy, or immunotherapy) administered after the breast cancer diagnosis, as evidenced by pharmacy dispensing records or treatment administration records in the HA database between January 1, 2018, and December 31, 2025
• - 5.Availability of at least 6 months of follow-up data in the HA database after the index date, unless death occurs within the 6-month period
• Exclusion Criteria:
• - 1.Male sex
• - 2.History of any other primary malignancy diagnosed prior to the index date (other than basal cell carcinoma of the skin and squamous cell carcinoma of the skin) as identified through ICD-9-CM codes 140.x–172.x, 176.x–208.x (excluding 174.x) recorded in the HA database during the 120-month baseline lookback period
• - 3.Patients with documented participation in an interventional clinical trial during the study period, where such information is available in the HA database, to preserve the real-world representativeness of observed treatment patterns